Previous close | 92.26 |
Open | 89.54 |
Bid | 90.68 x 100 |
Ask | 90.85 x 100 |
Day's range | 88.46 - 91.46 |
52-week range | 43.89 - 101.00 |
Volume | |
Avg. volume | 798,735 |
Market cap | 5.556B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.37 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 97.38 |
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.